Rivaroxaban is the R-enantiomer of the anticoagulant drug Rivaroxaban. It is a highly selective, direct inhibitor of Factor Xa (FXa), a key enzyme in the blood coagulation cascade. Its chemical structure is based on an oxazolidinone core, which is crucial for its binding affinity and selectivity. The primary and most significant application of Rivaroxaban is as an active pharmaceutical ingredient (API) for the prevention and treatment of thromboembolic disorders. It is widely used in clinical settings for stroke prevention in patients with non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of venous thromboembolism (VTE) after major orthopedic surgeries like hip or knee replacement. Its mechanism involves directly blocking FXa, thereby inhibiting thrombin generation and clot formation. The R-enantiomer is a key component in the synthesis and study of the final drug substance. As a high-value, single-enantiomer API, Rivaroxaban is subject to stringent quality control standards. Its development and manufacturing are central to the pharmaceutical industry's focus on novel oral anticoagulants (NOACs), which offer advantages over traditional therapies like warfarin.